Tezelman S, Shen W, Shaver J K, Siperstein A E, Duh Q Y, Klein H, Clark O H
Surgical Service, University of California at San Francisco.
Ann Surg. 1993 Sep;218(3):300-7; discussion 307-9. doi: 10.1097/00000658-199309000-00009.
There is considerable debate about whether double parathyroid adenomas are a discrete entity or represent hyperplasia with parathyroid glands of varying sizes. This distinction is important because it impacts on the extent of parathyroid resection and the success of the parathyroid operation.
Double parathyroid adenomas have been reported to occur in 1.7% to 9% of patients with primary hyperparathyroidism (HPT). It is important for surgeons to differentiate between double adenoma and hyperplasia with glands of varying sizes using gross examination during the initial procedure because microscopic findings of a small biopsy specimen at frozen-section examination may not be diagnostic.
From 1982 to 1992, 416 unselected patients (309 women and 107 men) with primary HPT without familial HPT or multiple endocrine neoplasia (MEN) were treated by one surgeon at the University of California at San Francisco. Double adenoma occurred in 49 patients, solitary adenoma in 309 patients, and hyperplasia in 58 patients. The authors analyzed the clinical manifestations, the preoperative and postoperative serum levels of calcium, phosphate, and parathyroid hormone (PTH), and the success rate and outcome after parathyroidectomy and compared their results in 49 patients with double adenomas to the results for patients with solitary adenomas or hyperplasia.
Ten of the patients with double adenomas (20.4%) were referred for persistent HPT after removal of one abnormal parathyroid gland. The ages of the patients with double adenoma, single adenoma, and hyperplasia were 61 +/- 14, 56 +/- 15, and 58 +/- 7 years, respectively. Fatigue, muscle weakness, and bone pain were common in patients with double adenomas, whereas nephrolithiasis occurred more frequently in patients with solitary adenoma (p = 0.0001). Serum calcium and PTH levels (per cent of upper limit of normal) fell from 11.5 +/- 1.2 mg/dL and 487% to 9.5 +/- 0.8 mg/dL and 61% for patients with double adenomas; from 11.9 +/- 0.9 mg/dL and 378% to 9.3 +/- 1.4 mg/dL and 101% for patients with single adenoma; and from 10.9 +/- 0.5 mg/dL and 418% to 9.1 +/- 0.7 mg/dL and 94% for patients with hyperplasia, respectively. There was no recurrence in the patients with double adenomas with a mean follow-up time of 5.8 years.
Double adenomas are a discrete entity and occur more often in older patients. Patients with double adenomas can be successfully treated by removal of the two abnormal glands.
关于双发性甲状旁腺腺瘤是一种独立的实体,还是代表大小各异的甲状旁腺增生,存在相当大的争议。这种区分很重要,因为它会影响甲状旁腺切除的范围以及甲状旁腺手术的成功率。
据报道,双发性甲状旁腺腺瘤在原发性甲状旁腺功能亢进症(HPT)患者中发生率为1.7%至9%。在初次手术过程中,外科医生通过大体检查区分双腺瘤和大小各异的甲状旁腺增生很重要,因为冰冻切片检查时小活检标本的显微镜检查结果可能无法确诊。
1982年至1992年,加利福尼亚大学旧金山分校的一名外科医生对416例未选择的原发性HPT患者(309例女性和107例男性)进行了治疗,这些患者无家族性HPT或多发性内分泌腺瘤(MEN)。49例患者为双腺瘤,309例患者为单发性腺瘤,58例患者为增生。作者分析了临床表现、术前和术后血清钙、磷和甲状旁腺激素(PTH)水平,以及甲状旁腺切除术后的成功率和结果,并将49例双腺瘤患者的结果与单发性腺瘤或增生患者的结果进行了比较。
10例双腺瘤患者(20.4%)在切除一个异常甲状旁腺后因持续性HPT前来就诊。双腺瘤、单发性腺瘤和增生患者的年龄分别为61±14岁、56±15岁和58±7岁。双腺瘤患者常见疲劳、肌肉无力和骨痛,而单发性腺瘤患者肾结石的发生率更高(p = 0.0001)。双腺瘤患者血清钙和PTH水平(正常上限的百分比)从11.5±1.2mg/dL和487%降至9.5±0.8mg/dL和61%;单发性腺瘤患者从11.9±0.9mg/dL和378%降至9.3±1.4mg/dL和101%;增生患者从10.9±0.5mg/dL和418%降至9.1±0.7mg/dL和94%。双腺瘤患者平均随访5.8年无复发。
双腺瘤是一种独立的实体,在老年患者中更常见。双腺瘤患者通过切除两个异常腺体可得到成功治疗。